Company: CERO
Filing Date: 2025-01-07
Form Type: 424B3
Source: 0001213900-25-001658
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 424B3
Chunk 4
---
(c) under 
 the Exchange Act (17 CFR 240.13e-4(c))                          |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sales of Equity Securities

The information set forth
under the section of Item 8.01 below titled “Warrant Issuances” is incorporated by reference herein.

Item 8.01 Other Events.

Registration Statements

On December 5, 2024, each
of the Company’s registration statement (the “PIPE Registration Statement”) on Form S-1 (File No. 333-282755) relating
to the resale of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issuable upon,
among other things, conversion of shares of the Company’s outstanding Series A Preferred Stock, par value $0.0001 per share (“Series
A Preferred Stock”), and Series B Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”), including
shares of Series A Preferred Stock issuable upon exercise of warrants to purchase shares of Series A Preferred Stock (“Preferred
Warrants”) and the Company’s registration statement on Form S-1 (File No. 333-283492) relating to the resale of shares that
the Company may require an investor to purchase pursuant to a committed equity financing facility (the “Equity Line”) were
declared effective by the Securities and Exchange Commission.

Warrant Exercises

From December 6, 2024 through
December 23, 2024